Priyankkumar Patel, MD
Hematology & Oncology · Urbana, ILNPI 1437460789
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AstraZeneca at 53.9% of the total. 2025 is the largest year on record at $18,740, more than ten times the $368 reported in 2019.
Across 129 payments — averaging $264.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Eli Lilly$6K
- Immunocore Limited$4K
- Lilly USA, LLC$3K
- Daiichi Sankyo Inc.$569
- Pfizer$223
- plus $2K from 21 others
Across 6 payments — averaging $4984.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$30K
What the payments were for
- Consulting fees$10,55831%
- Speaking & faculty fees$17,97053%
- Travel & lodging$2,8398%
- Food & beverage$2,4307%
- Education$3331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $18,401 |
| Eli Lilly | 2 | $6,300 |
| Immunocore Limited | 9 | $3,918 |
| Lilly USA, LLC | 3 | $3,028 |
| Daiichi Sankyo Inc. | 2 | $569 |
| Pfizer | 12 | $223 |
| Astellas Pharma US Inc | 11 | $214 |
| Bristol Myers Squibb | 8 | $199 |
| Merck | 13 | $188 |
| Johnson & Johnson | 6 | $147 |
| Novartis | 6 | $140 |
| Incyte Corporation | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $121 |
| EMD Serono, Inc. | 5 | $99 |
| Agios Pharmaceuticals, Inc. | 1 | $75 |
| Eisai Inc. | 4 | $67 |
| Sanofi | 4 | $54 |
| Taiho Oncology, Inc. | 3 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Clovis Oncology, Inc. | 1 | $32 |
| Bayer | 2 | $28 |
| Verastem, Inc. | 1 | $26 |
| Beigene USA, Inc. | 2 | $24 |
| Genentech, Inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $16 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,129 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 70 | $933,725 |
| ImbruvicaIbrutinib | 33 | $536,340 |
| Abiraterone Acetate | 116 | $498,554 |
| Lenalidomide | 42 | $489,885 |
| NubeqaDarolutamide | 29 | $402,296 |
| CabometyxCabozantinib S-Malate | 14 | $354,124 |
| BrukinsaZanubrutinib | 34 | $338,208 |
| PomalystPomalidomide | 25 | $313,815 |
| AlecensaAlectinib Hcl | 12 | $231,781 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 19 | $183,624 |
| CalquenceAcalabrutinib Maleate | 11 | $159,244 |
| KeytrudaPembrolizumab | 12 | $132,607 |
| EliquisApixaban | 111 | $86,323 |
| XareltoRivaroxaban | 49 | $43,552 |
| CreonLipase/Protease/Amylase | 23 | $25,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $199 | $933,72570 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $38 | $536,34033 claims |
| BayerNubeqa | $28 | $402,29629 claims |
| Beigene USA, Inc.Brukinsa | $24 | $338,20834 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $121 | $313,81525 claims |
| AstraZenecaCalquence | $18,401 | $159,24411 claims |
| MerckKeytruda | $188 | $132,60712 claims |
| PfizerEliquis | $223 | $86,323111 claims |
| Johnson & JohnsonXarelto | $147 | $43,55249 claims |
| AbbVieCreon | $14 | $25,98923 claims |
| Lilly USA, LLCOlanzapine | $3,028 | $44131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Urbana
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.